Professor Andrew Porter FRSE
Deputy Director, Institute of Medical Sciences, University of Aberdeen
Professor Andrew Porter has a wealth of experience within both industry and academia. He was the founding CSO at Haptogen Ltd (RSE Enterprise Fellowship Fellowship, 2001), which eventually sold to Wyeth/Pfizer Inc, was one of the founders of the biologics drug discovery company Elasmogen (CEO, Caroline Barelle another RSE Enterprise Fellow), and also holds Non-Executive positions in a number of life science and other businesses including Roslin Technologies Ltd (Chair), MicroPlate Dx Ltd (Stuart Hannah, RSEW Comm Fellow) and more recently NCIMB Ltd. He is a part-time Professor of Medical Biotechnology at the University of Aberdeen and Director of the Scottish Biologics Facility. Away from the life sciences, he is also a founding Director of Langstane Liquor Ltd and, more recently, during lockdown, the multi-award-winning WhiteBox Cocktails Ltd (both now located in Edinburgh).
Fellowship list
Involved in
-
Resources
This video reflects on the legacy of Scottish innovation, and explore its present and future.
-
Advice Papers
Report of the RSE roundtable with the South of Scotland Enterprise on their consultation on the Draft Regional Economic Strategy for the South of Scotland.
-
Advice Papers
The RSE's response to the British Business Bank (BBB) on their call for evidence around access to early-stage finance in Scotland.
-
Advice Papers
The RSE has provided a letter response to the Muscatelli Report into the economic impact of Scottish universities.
